These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 21199443)

  • 1. Experimental surgical therapies for Huntington's disease.
    Demeestere J; Vandenberghe W
    CNS Neurosci Ther; 2011 Dec; 17(6):705-13. PubMed ID: 21199443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Gene silencing approaches for the treatment of Huntington's disease].
    Merienne N; Déglon N
    Med Sci (Paris); 2015 Feb; 31(2):159-67. PubMed ID: 25744262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model.
    Harper SQ; Staber PD; He X; Eliason SL; Martins IH; Mao Q; Yang L; Kotin RM; Paulson HL; Davidson BL
    Proc Natl Acad Sci U S A; 2005 Apr; 102(16):5820-5. PubMed ID: 15811941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delivering a disease-modifying treatment for Huntington's disease.
    Godinho BM; Malhotra M; O'Driscoll CM; Cryan JF
    Drug Discov Today; 2015 Jan; 20(1):50-64. PubMed ID: 25256777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oligonucleotide therapeutic approaches for Huntington disease.
    Sah DW; Aronin N
    J Clin Invest; 2011 Feb; 121(2):500-7. PubMed ID: 21285523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Translating Antisense Technology into a Treatment for Huntington's Disease.
    Lane RM; Smith A; Baumann T; Gleichmann M; Norris D; Bennett CF; Kordasiewicz H
    Methods Mol Biol; 2018; 1780():497-523. PubMed ID: 29856033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat.
    Gagnon KT; Pendergraff HM; Deleavey GF; Swayze EE; Potier P; Randolph J; Roesch EB; Chattopadhyaya J; Damha MJ; Bennett CF; Montaillier C; Lemaitre M; Corey DR
    Biochemistry; 2010 Nov; 49(47):10166-78. PubMed ID: 21028906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preventing formation of toxic N-terminal huntingtin fragments through antisense oligonucleotide-mediated protein modification.
    Evers MM; Tran HD; Zalachoras I; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
    Nucleic Acid Ther; 2014 Feb; 24(1):4-12. PubMed ID: 24380395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Update on Huntington's Disease: Symptomatic Treatments and Emerging Disease-Modifying Therapies.
    Dash D; Mestre TA
    Neurotherapeutics; 2020 Oct; 17(4):1645-1659. PubMed ID: 32705582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Animal models of Huntington's disease: implications in uncovering pathogenic mechanisms and developing therapies.
    Wang LH; Qin ZH
    Acta Pharmacol Sin; 2006 Oct; 27(10):1287-302. PubMed ID: 17007735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic strategies for Huntington's disease.
    Estevez-Fraga C; Flower MD; Tabrizi SJ
    Curr Opin Neurol; 2020 Aug; 33(4):508-518. PubMed ID: 32657893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease.
    Southwell AL; Ko J; Patterson PH
    J Neurosci; 2009 Oct; 29(43):13589-602. PubMed ID: 19864571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of novel therapies for Huntington's disease: hope and challenge.
    Qin ZH; Wang J; Gu ZL
    Acta Pharmacol Sin; 2005 Feb; 26(2):129-42. PubMed ID: 15663888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained effects of nonallele-specific Huntingtin silencing.
    Drouet V; Perrin V; Hassig R; Dufour N; Auregan G; Alves S; Bonvento G; Brouillet E; Luthi-Carter R; Hantraye P; Déglon N
    Ann Neurol; 2009 Mar; 65(3):276-85. PubMed ID: 19334076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Huntingtin-Lowering Therapies for Huntington Disease: A Review of the Evidence of Potential Benefits and Risks.
    Leavitt BR; Kordasiewicz HB; Schobel SA
    JAMA Neurol; 2020 Jun; 77(6):764-772. PubMed ID: 32202594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PRMT5- mediated symmetric arginine dimethylation is attenuated by mutant huntingtin and is impaired in Huntington's disease (HD).
    Ratovitski T; Arbez N; Stewart JC; Chighladze E; Ross CA
    Cell Cycle; 2015; 14(11):1716-29. PubMed ID: 25927346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Huntington's disease: an update of therapeutic strategies.
    Kumar A; Kumar Singh S; Kumar V; Kumar D; Agarwal S; Rana MK
    Gene; 2015 Feb; 556(2):91-7. PubMed ID: 25447911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards a transgenic model of Huntington's disease in a non-human primate.
    Yang SH; Cheng PH; Banta H; Piotrowska-Nitsche K; Yang JJ; Cheng EC; Snyder B; Larkin K; Liu J; Orkin J; Fang ZH; Smith Y; Bachevalier J; Zola SM; Li SH; Li XJ; Chan AW
    Nature; 2008 Jun; 453(7197):921-4. PubMed ID: 18488016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene therapy in mouse models of huntington disease.
    Southwell AL; Patterson PH
    Neuroscientist; 2011 Apr; 17(2):153-62. PubMed ID: 21489966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of neuronal cell death in Huntington's disease.
    Sawa A; Tomoda T; Bae BI
    Cytogenet Genome Res; 2003; 100(1-4):287-95. PubMed ID: 14526190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.